Citations

Clear

6273 citation(s) found for "To, Andrew".

Promoting Growth in Behavioral Neurology: A Path Forward
Josephy‐Hernandez, Sylvia , Apostolova, Liana G. , Budson, Andrew E. , Chemali, Zeina , Lin, Chi‐Ying , Daffner, Kirk R. , Geschwind, Michael D., Heilman, Kenneth M. , Holden, Samantha K. , Jaffee, Michael S., Kletenik, Isaiah , Love, Marissa Natelson , Moo, Lauren R. , Pelak, Victoria S. , Press, Daniel Z. , Ramírez-Gómez, Liliana , Rosen, Howie, Vaishnavi, Sanjeev , Windon, Charles , Hamilton, Roy H. , Perez, David L. , Hamilton, Roy , Windon, Charles , Hamilton, Roy H , Bateman, James R. , Benjamin, Sheldon , Barrett, Anna M. , Boeve, Bradley F. , Hillis, Argye Elizabeth , Schmahmann, Jeremy Dan

Mayo Clinic

Cognitive and Behavioral Neurology | May 8, 2024 | Volume: 37 | Issue: 2 | Pages: 49-56

10.1097/wnn.0000000000000368 | PMID 38717325 Get It

Behavioral neurology & neuropsychiatry (BNNP) is a field that seeks to understand brain–behavior relationships, including fundamental brain organization principles and the many ways that brain structures and connectivity can be disrupted, leading to abnormalities of behavior, cognition, emotion, perception, and social cognition. In North America, BNNP has existed as an integrated subspecialty through the United Council for Neurologic Subspecialties since 2006. Nonetheless, the number of behavioral neurologists across academic medical centers and community settings is not keeping pace with increasing clinical and research demand. In this commentary, we provide a brief history of BNNP followed by an outline of the current challenges and opportunities for BNNP from the behavioral neurologist’s perspective across clinical, research, and educational spheres. We provide a practical guide for promoting BNNP and addressing the shortage of behavioral neurologists to facilitate the continued growth and development of the subspecialty. We also urge a greater commitment to recruit trainees from diverse backgrounds so as to dismantle persistent obstacles that hinder inclusivity in BNNP—efforts that will further enhance the growth and impact of the subspecialty. With rapidly expanding diagnostic and therapeutic approaches across a range of conditions at the intersection of neurology and psychiatry, BNNP is well positioned to attract new trainees and expand its reach across clinical, research, and educational activities.
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis
Vincelette, Nicole D. , Yu, Xiaoqing , Moon, Jungwon , Su, Siyuan , Cheng, Chia‐Ho, Sammut, Rinzine , Razabdouski, Tiffany N. , Nguyen, Hai V. , Eksioglu, Erika A. , Ali, Najla Al , Patel, Parth , Lee, Dae Hyun , Nakanishi, Shima , Hyjek, Elizabeth , Murphy, Daniel J. , Lee, Daesung , Kuykendall, Andrew , Moon, Jungwon , Su, Siyuan , Cheng, Chia-Ho , Sammut, Rinzine , Razabdouski, Tiffany N , Nguyen, Hai V , Eksioglu, Erika A , Chan, Onyee , Al Ali, Najla , Patel, Parth C , Lee, Dae H , Nakanishi, Shima , Ferreira, Renan B , Hyjek, Elizabeth , Mo, Qianxing , Cory, Suzanne , Lawrence, Harshani R , Zhang, Ling , Murphy, Daniel J , Komrokji, Rami S , Lee, Daesung , Kaufmann, Scott H , Cleveland, John L , Yun, Seongseok , Chan, Onyee , Zhang, Ling , Komrokji, Rami S. , Kaufmann, Scott H. , Cleveland, John L. , Yun, Seongseok

Mayo Clinic

Blood Cancer Discovery | May 7, 2024 | Volume: 5 | Issue: 4 | Pages: 276-297

10.1158/2643-3230.bcd-23-0210 | PMID 38713018 Get It

Abstract Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPN) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for patients with triple-negative (TN) myelofibrosis (MF) who lack mutations in the JAK2 kinase pathway and have very poor clinical outcomes. Here we report that MYC copy number gain and increased MYC expression frequently occur in TN-MF and that MYC-directed activation of S100A9, an alarmin protein that plays pivotal roles in inflammation and innate immunity, is necessary and sufficient to drive development and progression of MF. Notably, the MYC-S100A9 circuit provokes a complex network of inflammatory signaling that involves numerous hematopoietic cell types in the bone marrow microenvironment. Accordingly, genetic ablation of S100A9 or treatment with small molecules targeting the MYC-S100A9 pathway effectively ameliorates MF phenotypes, highlighting the MYC–alarmin axis as a novel therapeutic vulnerability for this subgroup of MPNs. Significance: This study establishes that MYC expression is increased in TN-MPNs via trisomy 8, that a MYC-S100A9 circuit manifest in these cases is sufficient to provoke myelofibrosis and inflammation in diverse hematopoietic cell types in the BM niche, and that the MYC-S100A9 circuit is targetable in TN-MPNs.
Low-profile mechanical thrombectomy devices for large vessel occlusion in pediatric ischemic stroke
Oushy, Soliman , Garton, Andrew , See, Alfred P. , Oushy, Soliman H , Orbach, Darren B.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 6, 2024 | Volume: 17 | Issue: 6 | Pages: 620-624

10.1136/jnis-2024-021574 | PMID 38719443 Get It

Background Mechanical thrombectomy (MT) is a well-established treatment modality for large vessel occlusion (LVO) in adults, but there are limited data in the pediatric population. The rarity of the condition makes prospective trial design difficult, and therefore evaluation of MT devices and outcomes is sparse. In pediatric LVO cases, some newer devices may be appropriate for use in revascularization procedures. Furthermore, illustrative specific device-access combinations have rarely been presented in young patients under the age of 5 years. Methods This was a single institution experience in intracranial MT procedures for pediatric acute ischemic stroke (AIS). A given procedure was included if there was an attempt at MT between 2015 and 2023. Results Sixteen endovascular procedures were performed in 15 patients with AIS, with a mean age of 7.4 years; eight patients were <5 years of age. MT was attempted in 15/16 (93.7%) procedures, including 11 (73.3%) in the anterior circulation and four (26.7%) in the posterior circulation; one case recanalized after medical treatment. The most common MT techniques were combined aspiration with a stentriever (n=10, 66.7%) and aspiration alone (n=3, 20%). Traditional stentrievers (4–6 mm) were used in seven cases and low-profile stentrievers in four cases. Improved reperfusion was achieved in all low-profile stentriever cases. Reperfusion of modified Thrombolysis in Cerebral Infaction ≥2b was obtained in 73.3% of cases, including 72.7% of those in which a stentriever was used. Conclusions Low-profile thrombectomy devices may achieve similar revascularization results to other approaches in challenging clinical scenarios observed in younger children.
Pan-Cancer Interrogation of B7-H3 ( CD276 ) as an Actionable Therapeutic Target Across Human Malignancies
Miller, Carly D. , Zorko, Nicholas A. , Elliott, Andrew , Makovec, Allison , Radovich, Milan , Heath, Elisabeth I. , Agarwal, Neeraj , McKay, Rana R. , Garje, Rohan , Bastos, Bruno , Orme, Jacob J. , Nabhan, Chadi , Dehm, Scott M. , Hwang, Justin H. , Lozada, John R , Zorko, Nicholas A , Elliott, Andrew , Makovec, Allison , Radovich, Milan , Heath, Elisabeth I , Agarwal, Archana M , McKay, Rana R , Garje, Rohan , Bastos, Bruno R , Hoon, Dave S B , Orme, Jacob J , Sartor, A Oliver , VanderWalde, Ari , Nabhan, Chadi , Sledge, George W , Shenderov, Eugene , Dehm, Scott M , Lou, Emil , Miller, Jeffrey S , Hwang, Justin H , Antonarakis, Emmanuel S , Hoon, Dave S.�B. , Sartor, Oliver , Vanderwalde, Ari M. , Sledge, George W. , Shenderov, Eugene , Lou, Emil , Miller, Jeffrey S. , Antonarakis, Emmanuel S.

Mayo Clinic

Cancer Research Communications | May 6, 2024 | Volume: 4 | Issue: 5 | Pages: 1369-1379

10.1158/2767-9764.crc-23-0546 | PMID 38709075 Get It

Abstract B7-H3 (CD276) is a transmembrane glycoprotein of the B7 immune checkpoint superfamily that has emerged as a promising therapeutic target. To better understand the applicability of B7-H3–directed therapies, we analyzed 156,791 samples comprising 50 cancer types to interrogate the clinical, genomic, transcriptomic, and immunologic correlates of B7-H3 mRNA expression. DNA (592-gene/whole-exome) and RNA (whole-transcriptome) sequencing was performed from samples submitted to Caris Life Sciences. B7-H3 high versus low expression was based on top and bottom quartiles for each cancer type. Patients’ overall survival was determined from insurance claims data. Pathway analysis was performed using gene set enrichment analyses. Immune cell fractions were inferred using quanTIseq. B7-H3 is expressed across several human malignancies including prostate, pancreatic, ovarian, and lung cancers. High B7-H3 expression is associated with differences in overall survival, possibly indicating a prognostic role of B7-H3 for some cancers. When examining molecular features across all cancer types, we did not identify recurrent associations between B7-H3 expression and genetic alterations in TP53, RB1, and KRAS. However, we find consistent enrichment of epithelial-to-mesenchymal transition, Wnt, TGFβ, and Notch signaling pathways. In addition, tumors with high B7-H3 expression are associated with greater proportions of M1 macrophages, but lower fractions of CD8+ T cells. We have begun to define the genomic, transcriptomic, clinical, and immunologic features associated with B7-H3 expression in 50 cancer types. We report novel clinical and molecular features of B7-H3–high tumors which may inform how current B7-H3 therapeutics should be deployed and prioritized. Significance: B7-H3–targeting therapeutics have shown promising results in initial clinical trials. In this pan-cancer analysis of B7-H3 mRNA expression, we found that B7-H3 exhibits robust expression in many common cancer types. These results may inform further development of B7-H3–targeting therapeutics and may guide clinical decisions for patients with limited treatment options.
Is Upper Extremity or Lower Extremity Function More Important for Patient Satisfaction? An Analysis of 24-Month Outcomes from the QOD Cervical Spondylotic Myelopathy Cohort
Mummaneni, Praveen V. , Chou, Dean , Izima, Chiemela , Fu, Kai-Ming, Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I. , Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Uribe, Juan S. , Tumialán, Luis M. , Turner, Jay D. , Haid, Regis W., Chan, Andrew K. , Yang, Eunice, Park, Paul

Mayo Clinic

Clinical Spine Surgery | May 6, 2024 | Volume: 37 | Issue: 4 | Pages: 188-197

10.1097/bsd.0000000000001613 | PMID 38706113 Get It

Study Design: Retrospective analysis of a prospective, multicenter registry. Objective: To assess whether upper or lower limb mJOA improvement more strongly associates with patient satisfaction after surgery for cervical spondylotic myelopathy (CSM). Summary of Background Data: The modified Japanese Orthopaedic Association (mJOA) is commonly used to assess functional status in patients with CSM. Patients present with upper and/or lower extremity dysfunction, and it is unclear whether improvement in one and/or both symptoms drives postoperative patient satisfaction. Methods: This study utilizes the prospective Quality Outcomes Database (QOD) CSM data set. Clinical outcomes included mJOA and North American Spine Society (NASS) satisfaction. The upper limb mJOA score was defined as upper motor plus sensory mJOA, and the lower limb mJOA as lower motor plus sensory mJOA. Ordered logistic regression was used to determine whether upper or lower limb mJOA was more closely associated with NASS satisfaction, adjusting for other covariates. Results: Overall, 1141 patients were enrolled in the QOD CSM cohort. In all, 780 had both preoperative and 24-month mJOA scores, met inclusion criteria, and were included for analysis. The baseline mJOA was 12.1±2.7, and postoperatively, 85.6% would undergo surgery again (NASS 1 or 2, satisfied). Patients exhibited mean improvement in both upper (baseline:3.9±1.4 vs. 24 mo:5.0±1.1, P<0.001) and lower limb mJOA (baseline:3.9±1.4 vs. 24 mon:4.5±1.5, P<0.001); however, the 24-month change in the upper limb mJOA was greater (upper:1.1±1.6 vs. lower:0.6±1.6, P<0.001). Across 24-month NASS satisfaction, the baseline upper and lower limb mJOA scores were similar (pupper=0.28, plower=0.092). However, as satisfaction decreased, the 24-month change in upper and lower limb mJOA decreased as well (pupper<0.001, plower<0.001). Patients with NASS scores of 4 (lowest satisfaction) did not demonstrate significant differences from baseline in upper or lower limb mJOA (P>0.05). In ordered logistic regression, NASS satisfaction was independently associated with upper limb mJOA improvement (OR=0.81; 95% CI: 0.68-0.97; P=0.019) but not lower limb mJOA improvement (OR=0.84; 95% CI: 0.70-1.0; P=0.054). Conclusions: As the magnitude of upper and lower mJOA improvement decreased postoperatively, so too did patient satisfaction with surgical intervention. Upper limb mJOA improvement was a significant independent predictor of patient satisfaction, whereas lower limb mJOA improvement was not. These findings may aid preoperative counseling, stratified by patients’ upper and lower extremity treatment expectations. Level of Evidence: Level—III.
MRI Vertebral Bone Quality Correlates With Interbody Cage Subsidence After Anterior Cervical Discectomy and Fusion
Bernatz, James T. , Pumford, Andrew, Mikula, Anthony L. , Bydon, Mohamad , Freedman, Brett A. , Sebastian, Arjun S. , Bernatz, James T. , Goh, Brian Chun Kim , Pinter, Zachariah W. , Michalopoulos, Giorgos D. , Huddleston, P.M. , Nassr, Ahmad , Freedman, Brett A.

Mayo Clinic

Clinical Spine Surgery | May 6, 2024 | Volume: 37 | Issue: 4 | Pages: 149-154

10.1097/bsd.0000000000001623 | PMID 38706112 Get It

Study Design: Retrospective observational study of consecutive patients Objective: The purpose of the study was to evaluate VBQ as a predictor of interbody subsidence and to determine threshold values that portend increased risk of subsidence. Summary of Background Data: Many risk factors have been reported for the subsidence of interbody cages in anterior cervical discectomy and fusion (ACDF). MRI Vertebral Bone Quality (VQB) is a relatively new radiographic parameter that can be easily obtained from preoperative MRI and has been shown to correlate with measurements of bone density such as DXA and CT Hounsfield Units. Methods: All patients who underwent 1- to 3-level ACDF using titanium interbodies with anterior plating between the years 2018 and 2020 at our tertiary referral center were included. Subsidence measurements were performed by 2 independent reviewers on CT scans obtained 6 months postoperatively. VBQ was measured on pre-operative sagittal T1 MRI by 2 independent reviewers, and values were averaged. Results: Eight-five fusion levels in 44 patients were included in the study. There were 32 levels (38%) with moderate subsidence and 12 levels with severe subsidence (14%). The average VBQ score in those patients with severe subsidence was significantly higher than those without subsidence (3.80 vs. 2.40, P<0.01). A threshold value of 3.2 was determined to be optimal for predicting subsidence (AUC=0.99) and had a sensitivity of 100% and a specificity of 94.1% in predicting subsidence. Conclusions: VBQ strongly correlates with the subsidence of interbody grafts after ACDF. A threshold VBQ score value of 3.2 has excellent sensitivity and specificity for predicting subsidence. Spine surgeons can use VBQ as a readily available screening tool to identify patients at higher risk for subsidence. Level of Evidence: Level—IV
Association of preprocedural antiplatelet use with decreased thromboembolic complications for intracranial aneurysms undergoing intrasaccular flow disruption
Diestro, Jose Danilo Bengzon , Adeeb, Nimer , Aslan, Assala , McLellan, Rachel , Lay, Sovann V. , Guenego, Adrien , Naamani, Kareem El, Shotar, Eimad, Premat, Kévin , Möhlenbruch, Markus , Kral, Michael , Doron, Omer , Salem, Mohamed M. , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza , Župančić, Vedran , Mohammed, Marwa A. , İmamoğlu, Çetin , Bayrak, Ahmet , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M. , Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan‐Karl , Essibayi, Muhammed Amir , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S , Pero, Guglielmo , Nossek, Erez , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Brook, Allan , Altschul, David , Spears, Julian , Marotta, Thomas R. , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Patel, Aman B. , Bayrak, Ahmet , Ibrahim, Mohamed K. , Siddiqui, Adnan H , Diestro, Jose Danilo B , Shotar, Eimad , Nguyen, Anh , Pero, Guglielmo , Kalousek, Vladimir , Altschul, David J , Regenhardt, Robert W , Essibayi, Muhammed Amir , Ulfert, Christian , Lay, Sovann V , Burkhardt, Jan‐Karl , Musmar, Basel , Salim, Hamza , Cancelliere, Nicole M , Algin, Oktay , Ghozy, Sherief , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Bernstock, Joshua D. , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Tawk, Rabih G. , Panni, Pietro , Killer-Oberpfalzer, Monika , Griessenauer, Christoph J. , Aziz‐Sultan, Mohammad Ali , Jabbour, Pascal , Limbucci, Nicola , Cuellar, Hugo , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Journal of Neurosurgery | May 3, 2024 | Volume: 141 | Issue: 4 | Pages: 992-999

10.3171/2024.2.jns232918 | PMID 38701528 Get It

OBJECTIVE This study was conducted to investigate the impact of antiplatelet administration in the periprocedural period on the occurrence of thromboembolic complications (TECs) in patients undergoing treatment using the Woven EndoBridge (WEB) device for intracranial wide-necked bifurcation aneurysms. The primary objective was to assess whether the use of antiplatelets in the pre- and postprocedural phases reduces the likelihood of developing TECs, considering various covariates. METHODS A retrospective multicenter observational study was conducted within the WorldWideWEB Consortium and comprised 38 academic centers with endovascular treatment capabilities. Univariable and multivariable logistic regression analyses were performed to determine the association between antiplatelet use and TECs, adjusting for covariates. Missing predictor data were addressed using multiple imputation. RESULTS The study comprised two cohorts: one addressing general thromboembolic events and consisting of 1412 patients, among whom 103 experienced TECs, and another focusing on symptomatic thromboembolic events and comprising 1395 patients, of whom 50 experienced symptomatic TECs. Preprocedural antiplatelet use was associated with a reduced likelihood of overall TECs (OR 0.32, 95% CI 0.19–0.53, p < 0.001) and symptomatic TECs (OR 0.49, 95% CI 0.25–0.95, p = 0.036), whereas postprocedural antiplatelet use showed no significant association with TECs. The study also revealed additional predictors of TECs, including stent use (overall: OR 4.96, 95% CI 2.38–10.3, p < 0.001; symptomatic: OR 3.24, 95% CI 1.26–8.36, p = 0.015), WEB single-layer sphere (SLS) type (overall: OR 0.18, 95% CI 0.04–0.74, p = 0.017), and posterior circulation aneurysm location (symptomatic: OR 18.43, 95% CI 1.48–230, p = 0.024). CONCLUSIONS The findings of this study suggest that the preprocedural administration of antiplatelets is associated with a reduced likelihood of TECs in patients undergoing treatment with the WEB device for wide-necked bifurcation aneurysms. However, postprocedural antiplatelet use did not show a significant impact on TEC occurrence.
Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
Hilton, Laura K. , Collinge, Brett , Alduaij, Waleed , Shaalan, Haya, Weng, Andrew P. , Cruz, Manuela Martins , Slack, Graham W. , Farinha, Pedro , Miyata‐Takata, Tomoko , Boyle, Merrill, Meissner, Barbara , Cook, James R. , Ondrejka, Sarah L. , Ott, German , Rosenwald, Andreas , Greiner, Timothy C. , Weisenburger, Dennis D. , Chan, Wing C. , Beiske, Klaus, Fu, Kai , Delabie, Jan , Pittaluga, Stafania, Iqbal, Javeed , Wright, George, Staudt, Louis M. , Wright, George W. , Alduaij, Waleed , Weng, Andrew P , Farinha, Pedro , Boyle, Merrill , Cook, James R , Ondrejka, Sarah , Campo, Elías , Amador, Catalina , Greiner, Timothy C , Inghirami, Giorgio , Jaffe, Elaine S , Delabie, Jan , Pittaluga, Stefania , Savage, Kerry J , Mungall, Andrew J , Feldman, Andrew L , Steidl, Christian , Morin, Ryan D , Scott, David W , Iqbal, Javeed , Wright, George , Hilton, Laura K , Ben‐Neriah, Susana , Cruz, Manuela, Campo, Elı́as , Raess, Philipp W. , Song, Joo Y. , Inghirami, Giorgio , Jaffe, Elaine S. , Pittaluga, Stefania , Sehn, Laurie H. , Savage, Kerry J. , Mungall, Andrew J. , Feldman, Andrew L. , Steidl, Christian , Rimsza, Lisa M. , Scott, David W.

Mayo Clinic

Blood | May 3, 2024 | Volume: 144 | Issue: 5 | Pages: 525-540

10.1182/blood.2024024251 | PMID 38701426 Get It

Abstract Rearrangements that place the oncogenes MYC, BCL2, or BCL6 adjacent to superenhancers are common in mature B-cell lymphomas. Lymphomas with diffuse large B-cell lymphoma (DLBCL) or high-grade morphology with both MYC and BCL2 rearrangements are classified as high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double hit”; HGBCL-DH-BCL2) and are associated with aggressive disease and poor outcomes. Although it is established that MYC rearrangements involving immunoglobulin (IG) loci are associated with inferior outcomes relative to those involving other non-IG superenhancers, the frequency of and mechanisms driving IG vs non-IG MYC rearrangements have not been elucidated. Here, we used custom targeted capture and/or whole-genome sequencing to characterize oncogene rearrangements across 883 mature B-cell lymphomas including Burkitt lymphoma, follicular lymphoma, DLBCL, and HGBCL-DH-BCL2 tumors. We demonstrate that, although BCL2 rearrangement topology is consistent across entities, HGBCL-DH-BCL2 have distinct MYC rearrangement architecture relative to tumors with single MYC rearrangements or with both MYC and BCL6 rearrangements (HGBCL-DH-BCL6), including both a higher frequency of non-IG rearrangements and different architecture of MYC::IGH rearrangements. The distinct MYC rearrangement patterns in HGBCL-DH-BCL2 occur on the background of high levels of somatic hypermutation across MYC partner loci in HGBCL-DH-BCL2, creating more opportunity to form these rearrangements. Furthermore, because 1 IGH allele is already disrupted by the existing BCL2 rearrangement, the MYC rearrangement architecture in HGBCL-DH-BCL2 likely reflects selective pressure to preserve both BCL2 and B-cell receptor expression. These data provide new mechanistic explanations for the distinct patterns of MYC rearrangements observed across different lymphoma entities.
Pragmatic strategies to address health disparities along the continuum of care in chronic liver disease
Brahmania, Mayur , Rogal, Shari S. , Serper, Marina , Goldberg, David S. , Mathur, Amit K. , Wilder, Julius , Vittorio, Jennifer , Yeoman, Andrew D. , Lazo, Mariana , Kardashian, Ani , Verma, Manisha , Verna, Elizabeth C. , Simpson, Dinee C. , Rosenblatt, Russell , McElroy, Lisa M. , Wadwhani, Sharad I., Strauss, Alexandra T. , Aiza, Ignacio , Carr, Rotonya M. , Yang, Jin Mo , Brady, Carla W. , Fortune, Brett E. , Rogal, Shari , Patel, Arpan , Goldberg, David , Mathur, Amit , Wilder, Julius , Vittorio, Jennifer M , Yeoman, Andrew , Lazo, Mariana , Kardashian, Ani , Asrani, Sumeet K , Spann, Ashley , Ufere, Nneka N , Verma, Manisha , Verna, Elizabeth C , Simpson, Dinee , Schold, Jesse D , Rosenblatt, Russell , McElroy, Lisa M , Wadhwani, Sharad I , Lee, Tzu-Hao , Strauss, Alexandra T , Aiza, Ignacio , Carr, Rotonya M , Yang, Jin Mo , Brady, Carla , Serper, Marina , Patel, Arpan , Rich, Nicole E. , Asrani, Sumeet K. , Spann, Ashley , Lee, Tzu‐Hao , Chung, Raymond T.

Mayo Clinic

Hepatology Communications | May 2, 2024 | Volume: 8 | Issue: 5 | Pages: No page available

10.1097/hc9.0000000000000413 | PMID 38696374 Get It

Racial, ethnic, and socioeconomic disparities exist in the prevalence and natural history of chronic liver disease, access to care, and clinical outcomes. Solutions to improve health equity range widely, from digital health tools to policy changes. The current review outlines the disparities along the chronic liver disease health care continuum from screening and diagnosis to the management of cirrhosis and considerations of pre-liver and post-liver transplantation. Using a health equity research and implementation science framework, we offer pragmatic strategies to address barriers to implementing high-quality equitable care for patients with chronic liver disease.